Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

FDA Approves Bepirovirsen for Chronic Hepatitis B

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE Maria Abreu, MD

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Todays Updates

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care Isabella Ciccone, MPH, Elizabeth Spurgeon, MD

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Todays Updates

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care Isabella Ciccone, MPH, Elizabeth Spurgeon, MD

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Latest News

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

News All Time

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Recommended News For You

From Pathology to Precision: The Story of Leukemia Therapy

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

Oncologist on Hantavirus Cruise; Bile Duct Cancer Drug OK'd; Untreated Lung Cancers

Scientists pioneer noninvasive 3D imaging to enhance skin cancer management

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

Cancer detection recovered following pandemic disruptions

Recommended Articles For You

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies 

Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself 

Iron Chelation Therapy: Preventing Long-Term Treatment Toxicities 

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

2.

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

3.

An inadvertent loss of weight may be an indication to consult a physician, according to research.

4.

Obesity-associated cancers tripled nationwide over past two decades

5.

An individual state lost $4.02 billion due to untreated mental illness.

1.

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals

2.

Breaking Down Amyloidosis: Understanding the Disease 

3.

Immune-Checkpoint Therapy Complications in the ICU: Clinical Challenges and Evidence-Based Management

4.

The Crucial Role of Antithrombin 3 in Preventing Blood Clots: A Comprehensive Guide

5.

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

3.

Current Scenario of Cancer- The Incidence of Cancer in Men

4.

Hematologic Fatigue and Work Function: Clinical Implications, Pathophysiology, and Management

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot